Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated Dec 7, 2018 (8 years ago)

Absorica (Isotretinoin)

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Subpotent Drug: Isotretinoin content results were lower than the specification limit obtained during routing product monitoring.

Cause type: Wrong potency / content

Sub- or super-potent product, or a failed content-uniformity / assay test. You may receive too little or too much active ingredient - a direct dosing risk. All wrong potency / content recalls.

What was recalled

Absorica (Isotretinoin) Capsules 30 mg USP, 30 capsules (3x10 Prescription Packs) Rx only, Manufactured by: Galephar Pharmaceutical Research Inc. Humacao, PR 00792, Distributed by: Sun Pharmaceutical Industries Inc. Cranbury, NJ 08512, UPC 310631117313, NDC 10631-117-31 (carton) NDC10631-117-69 (prescription pack)

Affected NDC 10631-0117-31

Compare with the code on your package — it is the most precise check available.

Drug: Isotretinoin

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Absorica
isotretinoin
NDC 10631-0117
30 mg/1 Capsule
Oral
Sun Pharmaceutical Industries, Inc. Rx
Recalling firm
Sun Pharmaceutical Industries, Inc.
NDC code
10631-117-31
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1207-2019 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Isotretinoin recalls

See all
Class II · Moderate risk

Isotretinoin Capsules

Superpotent Drug: The 3-month stability result for assay was found to be above specification limit

Ongoing Wrong potency / content Teva Pharmaceuticals USA, Inc NDC 0591-2436-45 D-0439-2024

Other recalls by Sun Pharmaceutical Industries, Inc.

All 2018 recalls
Class II · Moderate risk

Carbamazepine Tablets

CGMP Deviations; black spots found on tablets from burnt excipient during manufacturing

Ongoing cGMP deviation Sun Pharmaceutical Industries INC NDC 51672-4005-3 D-0770-2026
Class II · Moderate risk

Perampanel CIII Tablets

Labeling: Label Mix-up: 10mg Perampanel CIII tablet was found in a Perampanel CIII bottle labeled Perampanel 6 mg tablets.

Ongoing Labeling / mix-up Sun Pharmaceutical Industries INC NDC 51672-4206-6 D-0628-2026